Stay updated with breaking news from Christian Ruff. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF.
A group of 13 leading experts provides their perspectives on the top news in cardiovascular medicine from 2023, with responses ranging from novel approvals to new semaglutide data to gene therapy and more.
InnovationRx is your weekly digest of healthcare news. Sign up!
Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.
The quest for an anticoagulant that can prevent cardiovascular events without bleeding is something of a holy grail in cardiovascular medicine. Could factor XI inhibitors be the long-sought answer?